Matthew Taylor, MD

Trials

Studies that name Matthew Taylor, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:10 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT05389514 · Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

  Providence Health & Services · no longer available · KRAS G12V Mutant Advanced Epithelial Cancers · principal investigator
• Ph2
  NCT05308901 · Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

  Providence Health & Services · terminated · Melanoma, Uveal · principal investigator
• Ph2
  NCT05200143 · Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

  Providence Health & Services · terminated · Refractory Cutaneous Melanoma · principal investigator
• Ph1
  NCT03882437 · Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

  Rocket Pharmaceuticals Inc. · completed · Danon Disease · principal investigator
• Ph1
  NCT01107522 · Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

  Tactical Therapeutics, Inc. · unknown · Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.